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eFBongenital heart disease (CHD) is the most com-
mon birth defect and is a significant source of
morbidity and mortality in children. Despite con-
iderable recent progress in the clinical arena, we have a lot
et to learn about the causes of CHD and the genetic
odifiers of clinical outcome. It is our hope that an
mproved understanding of the etiology of CHD will lead
o improved care for the patient with this disease. To
ccelerate discovery in these areas, the National Heart,
ung, and Blood Institute (NHLBI) launched a novel
ranslational research program in pediatric cardiovascular
isease, the Bench to Bassinet program, in September 2009
http://www.benchtobassinet.com).
The Bench to Bassinet program is designed to accelerate
he pace of discovery and the translation of basic research
nto clinical studies through large-scale collaborations at all
evels, with a nimble interactive structure to provide for
eamless integration of findings from 1 research stream into
nother. The Cardiovascular Development Consortium
CvDC) comprises 4 research centers (Table 1) that will use
arious techniques and animal models to elucidate the
egulatory and developmental derangements that cause CHD.
he Pediatric Cardiac Genomics Consortium (PCGC) in-
olves 5 research centers (Table 1) whose goals are to delineate
he genetic underpinnings of CHD through the use of
enome-wide analytic techniques and high-throughput se-
uencing. The CvDC and the PCGC will share an admin-
strative coordinating center. These new programs will align
nd interact with an existing NHLBI-funded clinical re-
rom the National Heart, Lung, and Blood Institute, National Institutes of Health,g
ethesda, Maryland.
Manuscript received November 5, 2009; accepted November 10, 2009.earch network, the Pediatric Heart Network (PHN) (1)
nd its data coordinating center.
vDC
evelopment of a fully formed and functional cardiovascu-
ar system is the outcome of an exquisite network of
nteracting molecular pathways at the levels of molecule,
ell, tissue, organ, and organism. Numerous pathways and
omponents of this network have been identified, but they
ail to explain fully the emergence of a complex structure
uch as the heart (2,3). The field of cardiovascular develop-
ent now has the necessary elements (i.e., basic research,
nvestigators, technology, and so forth) to move beyond
nalysis of single steps within pathways to compiling exist-
ng and new data in an effort to understand the overall
egulatory network architecture (4). To do so, however,
equires large-scale team science and sophisticated infor-
atics tools. The CvDC brings together state-of-the-art
esearch teams and resources capable of executing this
cientific paradigm shift in a flexible environment in which
nvestigators can react quickly to new scientific or technical
pportunities.
The participating research centers of the CvDC will use
variety of genome-wide approaches to build a higher-order
ardiac development network model. High-throughput se-
uencing technology will shed light on global transcrip-
ional and epigenetic regulation, ribonucleic acid (RNA)
xpression, and microRNA feedback mechanisms. Forward
enetic screening in mice will expand the number of mutant
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March 23, 2010:1262–5 NHLBI Bench to Bassinet Programouse lines that display phenotypes at the stages most
elevant for human heart defects. Selected candidate mole-
ules identified by the high-throughput techniques will be
unctionally validated by perturbation studies and sub-
equent characterization. The CvDC will use a variety of
pecies models including mouse, chick, and zebrafish; and
hrough interactions with its sister groups in the Bench to
assinet program, will identify and pursue those basic
iscoveries with the greatest potential to translate to clinical
pplications.
The genetic underpinning of CHD is demonstrated by
he occurrence of familial clustering of certain types of heart
efects (5), the documented association of human genetic
yndromes with CHD (6), and the link between single gene
utations and CHD in animal models (2). Painstaking
ork in each of these areas has helped uncover monogenic
utations and alterations of genetic regions that cause
HD. Many of the monogenic mutations are found in
enes that encode transcription factors. One of the goals of
he CvDC will be to assemble these transcription factors
ith upstream and downstream components to fully flesh
ut the complex regulatory networks that affect cardiac
evelopment.
CGC
espite the compelling evidence of a genetic etiology for
HD, only a minority of cases of human CHD can be
xplained by an identified genetic defect. Barriers to gene
able 1 Institutions and Project Titles of the Cardiovascular
evelopment and Pediatric Cardiac
enomics Consortia
Institution Project Title
ardiovascular Development Consortium
Gladstone Institutes The Epigenetic Landscape of
Heart Development
Harvard University Mapping Transcriptional
Networks in Cardiac
Development
University of Pittsburgh Modeling the Genetic Basis for
Human Congenital Heart
Disease in Mice
University of Utah Genome-wide Analysis of
Cardiac Development in
Zebrafish
ediatric Cardiac Genomics Consortium
Children’s Hospital Boston/Brigham
and Women’s Hospital
Copy Number Variants for
Discovery of Congenital
Heart Genes
Children’s Hospital of Philadelphia The Genetic Basis of
Conotruncal Defects
Columbia University Molecular Approaches to Gene
Identification in Congenital
Heart Disease
Mount Sinai School of Medicine Genomic Studies of Secundum
Atrial Septal Defects
Yale University Genetic Determinants of
Human Heterotaxy andwAortic Arch Malformationiscovery in the setting of CHD
nclude the sporadic and some-
imes lethal nature of the disease,
he numerous genes that affect
ardiac development (7), and the
mprecise correlation of genotype
nd phenotype (8).
The participating research
enters of the PCGC will use
ecent advances in large-scale ge-
etic techniques developed in re-
ponse to the sequencing of the
uman genome to overcome the barriers to identification of
enetic causes of CHD (9). These advances include
enome-wide interrogation of single nucleotide polymor-
hisms and structural variations, array technologies, and
igh-throughput sequencing. Using a genome-wide strategy
s an inherently unbiased approach to detecting associations
etween genetic variation and phenotype, such as CHD
iagnosis. By casting the net broadly, the limits of a
andidate gene approach are overcome. Associations are
etected by comparing cases with an unrelated control
opulation or with unaffected family members, and thus
bviate the need for multigenerational affected families as is
equired for traditional linkage analysis.
Genomic studies require large populations to detect true
ositive findings (10). It is here that the power of the
onsortium will be brought to bear. Approximately 40,000
nfants are born with CHD each year and, of these, 15,000
ave complex defects. While single centers have access to only
limited number of patients, the Consortium will be able to
ecruit a significant subset of this population. Recruiting and
henotyping protocols will be developed by the centers of the
CGC so that clinical data and biospecimens can be shared to
eet the individual needs of the research centers. Bioinformat-
cs technology will further enhance efficiency and promote
haring of data, analyses, and ideas.
ligning With the PHN
he CvDC and PCGC will align with and interact with
he PHN (11). Established in 2001 with funding from
he NHLBI, the PHN is a collaborative network of 8
rimary sites that perform clinical trials and studies in
atients with pediatric cardiovascular disease (1). Recent
tudies have included a randomized surgical trial com-
aring 2 surgical strategies for palliation of hypoplastic
eft heart syndrome (12) and a randomized, placebo-
ontrolled trial of angiotensin-converting enzyme inhib-
tors in patients with single-ventricle physiology (13).
The PHN’s established track record in recruiting patients
Abbreviations
and Acronyms
CHD  congenital heart
disease
CvDC  Cardiovascular
Development Consortium
NHLBI  National Heart,
Lung, and Blood Institute
PCGC  Pediatric Cardiac
Genomics Consortium
PHN  Pediatric Heart
Networkith CHD will be invaluable as the PCGC develops and
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NHLBI Bench to Bassinet Program March 23, 2010:1262–5hen implements its recruiting and phenotyping protocols.
he PHN and PCGC will share the same coordinating
enter, the New England Research Institutes, so this expe-
ience and expertise can be readily brought to bear for the
CGC. The PHN clinical sites offer a logical means of
xtending the reach of the PCGC through expanded
ecruitment. Finally, with its existing clinical trials/research
nfrastructure, the PHN is poised to rapidly translate any
romising findings from either the CvDC or the PCGC to
he clinical world (the bassinet) as a primary study or as an
ncillary study to an ongoing protocol. The PHN has
lready demonstrated that it can quickly take a concept from
romising preliminary animal data to trial recruitment (14).
ew Paradigm for Translational Research
ranslational research describes the continuum from basic
cience discovery to clinical application—from bench to
edside, or in the case of a newborn with complex CHD,
rom bench to bassinet. The central tenets of early transla-
ional research are delineated by the first goal of the
HLBI’s Strategic Plan: “To improve understanding of the
olecular and physiological basis of health and disease, and
o use that understanding to develop improved approaches
o disease diagnosis, treatment, and prevention” (15).
The conventional model for funding translational re-
earch has been to create a multidisciplinary team of
esearchers, typically at a single institution or a few institu-
ions. The expectation was that communication and coop-
ration between basic scientists and clinical researchers
ould allow knowledge to flow seamlessly from the labora-
ory to the clinic and back again. While such an arrange-
ent may have enhanced collaboration between groups that
ften do not interact, it may have been overly optimistic to
nticipate that the findings from an individual laboratory
ould be applicable to the patient population at that same
nstitution within a single funding cycle.
The Bench to Bassinet program will employ a novel ap-
roach to the barriers and opportunities of translational re-
earch. The program will create a critical mass of collaborative
esearch at each stage of discovery with open lines of commu-
ication across the paradigm. Multiple groups will focus on
ecoding the regulatory pathways that underlie cardiac devel-
pment. Simultaneously, a consortium of researchers will
ttempt to evaluate the association of genetic variation with the
tiology and outcome of CHD, with the ultimate goal of
iscovering critical causative genes. These groups will work in
arallel but with close communication so that important
iscoveries by 1 consortium can be evaluated and tested by the
isciplines and technologies of the other. In addition, the
onsortia will employ high-throughput technologies, which
ill produce reams of data. An important requirement of bothonsortia is rapid sharing of data with the larger scientific
ommunity. This aggressive sharing plan will further amplify
he collaborative process and maximize the opportunity for
dentifying translatable knowledge.
The PHN, with its ongoing patient recruitment and
linical studies activities, represents the clinical end of the
ranslational spectrum. The established infrastructure of the
HN will allow for efficient adaptation of important find-
ngs from the CvDC or PCGC into an appropriate clinical
tudy. Elucidation of a regulatory transcriptional pathway
ay suggest a novel target for drug therapy or identification
f a genetic variant that is significantly associated with a
linical outcome may inform stratification for a clinical trial.
n important aspect of translational research is that the flow
f knowledge along the continuum is in both directions.
hus, observations from ongoing clinical trials may suggest
otential areas of inquiry for the developmental and genetic
esearchers, and assist in prioritizing aspects of the animal
tudies that have the most clinical relevance.
We are very excited about the initiation of the Bench to
assinet program. Our goal for the program is that it will
ccelerate the pace of discovery of the cause of CHD. In so
oing, we hope the organizational paradigm of the Consor-
ia may serve as a model that will improve efficiency and
nhance collaboration of the translational research process.
ost importantly, we hope and anticipate that the research
fforts of the Consortia will translate into improved health
nd care for the infant with CHD who lies asleep in her
assinet . . . waiting.
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an, Heart Development and Structural Diseases Branch,
ivision of Cardiovascular Sciences, NHLBI/NIH, 6701
ockledge Drive, Room 8222, Bethesda, Maryland 20892.
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